Blood is the currency of clinical trials—and getting it from patient to lab within 48 hours can make or break a study. In this episode, LabConnect CEO Wes Wheeler joins us to discuss how a lab-agnostic model, purpose-built software, and disciplined process design are transforming global clinical research. Wes breaks down why LabConnect chooses not to own labs and how this decision enables speed, scale, and flexibility across seven key regions where trials are conducted and patients resi...
All content for Tomorrow’s World Today® Podcast is the property of Tomorrow's World Today® and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Blood is the currency of clinical trials—and getting it from patient to lab within 48 hours can make or break a study. In this episode, LabConnect CEO Wes Wheeler joins us to discuss how a lab-agnostic model, purpose-built software, and disciplined process design are transforming global clinical research. Wes breaks down why LabConnect chooses not to own labs and how this decision enables speed, scale, and flexibility across seven key regions where trials are conducted and patients resi...
Electric Healing: Northwell Health’s Path to Bioelectronic Medicine
Tomorrow’s World Today® Podcast
28 minutes
4 months ago
Electric Healing: Northwell Health’s Path to Bioelectronic Medicine
Dr. Kevin J. Tracey, President and CEO of the Feinstein Institute for Medical Research at Northwell Health and Director of the Laboratory of Biomedical Science, discusses how bioelectronic medicine could transform how we treat inflammation and immune disorders. 🧬💡 Collaborate with us! Support the show For more information about the innovations that are shaping tomorrow's world, head to https://tomorrowsworldtoday.com/ To keep up-to-date with the latest in innovation, technology, sustainabili...
Tomorrow’s World Today® Podcast
Blood is the currency of clinical trials—and getting it from patient to lab within 48 hours can make or break a study. In this episode, LabConnect CEO Wes Wheeler joins us to discuss how a lab-agnostic model, purpose-built software, and disciplined process design are transforming global clinical research. Wes breaks down why LabConnect chooses not to own labs and how this decision enables speed, scale, and flexibility across seven key regions where trials are conducted and patients resi...
